The goal of this clinical research study is to establish the safety of simultaneous infusions
of methotrexate and etoposide into the fourth ventricle of the brain or resection cavity in
patients with recurrent malignant posterior fossa brain tumors. These tumors include
medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor or other malignant brain tumor
with recurrence or progression involving anywhere in the brain and/or spine. Patients'
disease must have originated in the posterior fossa of the brain.
- Brief Title: Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors
- Official Title: Combination Intraventricular Chemotherapy Pilot Study: Methotrexate and Etoposide Infusions Into the Fourth Ventricle or Resection Cavity in Children With Recurrent Posterior Fossa Brain Tumors
Clinical Trial IDs
- ORG STUDY ID:
- NCT ID:
|Methotrexate||Trexall, Rasuvo||Methotrexate / Etoposide Infusion|
|Etoposide||VePesid, Toposar, Etopophos||Methotrexate / Etoposide Infusion|
The goal of this clinical research study is to establish the safety of simultaneous
infusions of methotrexate and etoposide into the fourth ventricle of the brain or resection
cavity in patients with recurrent malignant posterior fossa brain tumors. These tumors
include medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor or other malignant
brain tumor with recurrence or progression involving anywhere in the brain and/or spine.
Patients' disease must have originated in the posterior fossa of the brain.
If the participant is eligible to take part in this study, the participant will have surgery
to place a catheter into the Ommaya reservoir. The Ommaya reservoir is a catheter system
that allows drugs to be administered directly to parts of the brain. This catheter will be
used for the infusion of methotrexate and etoposide directly into the 4th ventricle of the
brain, which is 1 of the 4 connected fluid-filled cavities in the brain.
If the study doctor thinks it is necessary, based on the location of the tumor, the tumor
may also be removed while the participant is already under anesthesia just before the
catheter is placed.
Study Drug Administration:
The participant will receive twice weekly 4 mg intraventricular methotrexate infusions for
six consecutive weeks and daily 1 mg intraventricular etoposide infusion five times per
week, every 2 weeks. Etoposide will be administered on weeks 1, 3, and 5.
Methotrexate and Etoposide will be infused though the ommaya reservoir catheter directly
into the 4th ventricle of the brain starting at a minimum of 7 days after the catheter
placement surgery. A MRI will be done to confirm adequate cerebrospinal fluid flow. The
etoposide infusion will last 3-4 minutes and the methotrexate infusion will last 3 minutes.
If the participant already has an Ommaya catheter, methotrexate and etoposide will begin
after an MRI has confirmed adequate cerebrospinal fluid flow.
Prior to first infusion:
Medical history will be reviewed and any updates to health will be recorded. Physical and
Neurological exam with vital signs will be done. Blood (about 1 teaspoon) will be drawn for
routine test. A lumbar puncture will be done. A MRI scan of the brain and spine will be done
to check the status of the disease.
On the days of the Methotrexate and Etoposide Infusion:
A neurological exam with vital signs will be done. A Ommaya reservoir tap (a catheter is
placed into the Ommaya reservoir to give the methotrexate and etoposide infusion.
Cerebrospinal fluid (about 1 teaspoon) will be collected for routine tests.
Within 7 days of completing the Final infusion:
A neurological exam with vital signs will be done. A lumbar puncture and lab work will be
done. A MRI scan of the brain and spine will be done to check status of the disease.
Length of Study:
The participant will receive 12 infusions of Methotrexate 4 mg and 15 infusions of Etoposide
1 mg, as long as the doctor thinks it is in their best interest. The participant will no
longer be able to receive the study drug if the disease gets worse, if intolerable side
effects occur, or if unable to follow study directions.
This is an investigation study. Methotrexate is FDA approved and commercially available for
infusion directly into brain tumors. The infusion of methotrexate into the 4th ventricle of
the brain in investigational. Etoposide is FDA approved and commercially available to be
given by mouth or into the bloodstream (intravenously) but has never been given in the 4th
ventricle of the brain. The infusion of methotrexate and etoposide into the 4th ventricle of
the brain is investigational.
Up to 10 patients will be enrolled in this study. All will be enrolled at Children's
Memorial Hermann Hospital.
|Methotrexate / Etoposide Infusion||Experimental||12 infusions of intraventricular Methotrexate and 15 infusions of intraventricular Etoposide into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle. Methotrexate will be infused twice weekly for 6 weeks and etoposide will be infused 5 times a week on weeks 1, 3 , and 5.|
- Age 1 - 21 years at time of recurrence or progression
- Diagnosis: Patients with histologically verified medulloblastoma, ependymoma, or
atypical teratoid/rhabdoid tumor or other malignant brain tumor with recurrence or
progression involving anywhere in the brain and/or spine. To be eligible, patients'
disease must have originated in the posterior fossa of the brain
- Patient must have either measurable or evaluable tumor as assessed by MRI of the
brain and total spine
- An implanted catheter in the fourth ventricle or posterior fossa tumor cavity
attached to an Ommaya reservoir or agreement to have one placed.
- A minimum of 7 days between last dose of systemic chemotherapy and/or radiation
therapy and first infusion of chemotherapy into fourth ventricle
- Life expectancy of at least 12 weeks in the opinion of the PI
- Lansky score of 50 or greater if ≤16 years of age or Karnofsky score of 50 or greater
if > 16 years of age
- Existing neurological deficits must have been stable for a minimum of 1 week prior to
- Patients must have recovered from the acute toxic effects of all prior anticancer
- Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) ≥
500/µL, platelet count ≥ 50,000/µL (transfusion independent), and hemoglobin ≥ 9.0
gm/dL (may receive Red Blood Cell transfusions)
- Patient or patient's legal representative, parent(s), or guardian able to provide
written informed consent.
- Enrolled in another treatment protocol
- Has received another investigational or chemotherapy agent or radiation therapy
within 7 days prior to intraventricular chemotherapy infusions
- Evidence of untreated infection
- Pregnant or lactating women
|Maximum Eligible Age:||21 Years|
|Minimum Eligible Age:||1 Year|
Primary Outcome Measures
|Measure:||Number of patients with grade 3 through grade 5 new neurological adverse events that are related to study drug, graded according to NCI CTCAE Version 4.0|
|Time Frame:||4 months|
|Description:||New neurological deficit defined as new cranial neuropathy, nystagmus, change in mental status, motor deficit or cerebellar finding (ataxia, dysmetria, dysdiadochokinesis) that is attributed by treating physicians to intraventricular methotrexate and etoposide infusions. Primary endpoint for basis of safety monitoring is acute toxicity occurring at any time within 30 days of receiving the intraventricular methotrexate and etoposide infusion. Rate of acute toxicity monitored using Bayesian method of Thall and Sung. Method of Kaplan and Meier used to estimate unadjusted distributions of time to a neurological deficit and progression free survival time and summary statistic of all variable computed and tabulated|
|Phase:||Early Phase 1|
|Lead Sponsor:||The University of Texas Health Science Center, Houston|
- Malignant Neoplasms, Brain
October 31, 2016